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Our group has described the stepwise increase in adverse events for individuals with increasing nonobstructive CAD, and the prevalence of lesion ischemia in nonobstructive stenoses in the current study is consistent with that reported previously.
We agree that the high prevalence of ischemia in nonobstructive CAD is concerning, which underscores the need for novel measures, such as FFR CT and APCs, to identify at-risk individuals who do not meet conventional angiographic definitions of severe CAD, yet who experience ischemia and require aggressive therapy to mitigate the adverse prognosis that we have thus far observed. 
